Clinical trials: Colorectal Tumor
Breast Cancer, Melanoma
Immunological Variables Associated to ICI Toxicity in Cancer Patients
This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy.
- Conditions
- Breast Cancer, Melanoma, Non Small Cell Lung Cancer, Non-melanoma Skin Cancer
- Trial name
- NCT05429866
- Testing
- Checkpoint Blockade, Immune
- Where
- Belgium
- Volunteers
- 441 people
- Sponsor
- Jules Bordet Institute
Colon Cancer
LRP1 Methylation and Colon Cancer
Colorectal cancer (CRC) is a major public health problem in France and worldwide. CRC is the third most common cancer in incidence and mortality in France.
- Trial name
- NCT02786602
- Testing
- pyrosequencing
- Volunteers
- 345 people
- Sponsor
- CHU de Reims
Colon Disease, Colonic Neoplasms
3-day vs. 1-day Low Residue Diet Influence in Colonoscopy Preparation and Patient Tolerability
Colonoscopy is one of the most common methods for the diagnosis and treatment of lower gastrointestinal tract diseases and provides a unique opportunity to identify early neoplastic lesions.
- Trial name
- NCT02955901
- Testing
- 3 day low residue diet prior to the colonoscopy, 1 day low residue diet prior to the colonoscopy
- Where
- Portugal
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- Portuguese Oncology Institute, Coimbra
Rectal Cancers
Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal Cancer
Rectal cancer surgery has become increasingly effective, allowing many patients to avoid permanent colostomy. However, anastomotic leakage remains one of the most serious complications after rectal cancer surgery, especially in…
- Trial name
- PKUCH-R10 (NCT07833319)
- Testing
- methylene blue injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Uterine Cancer, Rectal Cancer
Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Female patients with early onset (<50 years old) pelvic malignancies such as uterine and rectal cancers are rising in incidence, which often requires pelvic radiation; many of these patients are premenopausal and at a high risk…
- Conditions
- Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer
- Trial name
- OvAR-Y (NCT06904365)
- Testing
- HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer
Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer
Two-part phase 1B clinical trial combining cextuximab and savolitinib for treating Ras wild-type colorectal cancer (CRC). Part 1 will assess the safety and tolerability of this drug combination and will include patients with…
- Trial name
- NCT02630420
- Testing
- cetuximab and savolitinib
- Sponsor
- Yale University
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Colon Cancer, Colorectal Cancer
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
The goal of this clinical research study is to find out what effects radioactive particles, SIR-spheres, have when injected into the liver, followed by systemic chemotherapy with a combination of cetuximab and irinotecan compared…
- Trial name
- NCT00766220
- Testing
- SIR-spheres Agent Administration, Cetuximab, Irinotecan
- Sponsor
- M.D. Anderson Cancer Center
Cancer, Breast Cancer
The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer
This study is for people whose cancer: has resisted chemotherapy are taking a break from chemotherapy or are looking for an alternative to the toxic effects of chemotherapy The trial is looking to see if a very low carbohydrate…
- Conditions
- Cancer, Breast Cancer, Colon Cancer, Cervical Cancer
- Trial name
- RECHARGE (NCT00444054)
- Testing
- Very low carbohydrate diet (approximately 20 grams per day)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albert Einstein College of Medicine
Colorectal Cancer
S9304A Study of Protein Expression in Tumor Tissue Samples From Patients With Stage II or Stage III Rectal Cancer Enrolled in Clinical Trial SWOG-9304
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00972751
- Volunteers
- 220 people
- Sponsor
- SWOG Cancer Research Network
Rectal Cancer
Robotic-assisted Versus Conventional Laparoscopic Approach for Rectal Cancer Surgery
This is a prospective randomized controlled study that was conducted on patients of both sexes and definite age group at National Cancer Institute-Egypt and with adenocarcinoma of the rectum located within 15 cm from the anal…
- Trial name
- NCT03589131
- Testing
- Total Operative time, Margin assessment, Conversion rate to open surgery
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute, Egypt
Familial Pancreatic Cancer, BRCA1 Mutation
Registry of Subjects at Risk of Pancreatic Cancer
IRFARPC is a multicenter national registry designed to study the diagnosis and predisposing factors of subjects with an inherited increased risk for pancreatic cancer.
- Conditions
- Familial Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation, Lynch Syndrome
- Trial name
- IRFARPC (NCT04095195)
- Testing
- MRCP, Endoultrasonography
- Where
- 4 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Associazione Italiana per lo Studio del Pancreas
Colorectal Carcinoma, Lynch Syndrome
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients
This study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients.
- Trial name
- NCT05410977
- Testing
- Biospecimen Collection, Electronic Health Record Review
- Where
- 9 sites in United States
- Volunteers
- 950 people
- Sponsor
- Mayo Clinic
Colorectal Cancer
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
- Trial name
- NCT00049101
- Testing
- erlotinib hydrochloride, fluorouracil, leucovorin calcium
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer Control and Prevention
Life Expectancy-informed Colorectal Cancer Screening
The purpose of this study is to improve life-expectancy concordant colorectal cancer screening for adults over 75 years through design and testing of a life expectancy notification to clinicians delivered via the electronic…
- Trial name
- CRC (NCT07141901)
- Testing
- Decision Tool
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Kathryn Martinez
Colorectal Cancer Screening
Test Up Now Education Program
This study will test the effectiveness of an outreach strategy to increase colorectal cancer screening in African Americans. The investigators will recruit 250 African Americans ages 45-64 years who are not up-to-date with…
- Trial name
- TUNE-UP (NCT04304001)
- Testing
- Community Health Advisor, Usual care
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Florida A&M University
Rectal Cancer
LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection
A preliminary Study in Subjects Undergoing Low Anterior Resection
- Trial name
- NCT01790230
- Testing
- LifeSeal™ Kit
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- LifeBond Ltd.
Colorectal Cancer Metastatic
Explore Biomarkers Associated With Prognosis of Recurrent and Metastatic CRC After Surgery by Multi-omics Methods
This project is the first application, which is applied as a single center project and applied according to the screening quantity.
- Trial name
- NCT05501353
- Testing
- no intervention
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.